Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave Acetate Dosing in Exudative AMD
NCT00299507Phase 3
Key facts
- Status
- Completed
- Start
- Mar 2005
- Primary completion
- Apr 2008
- Countries
- 1
- Sponsor
- Alcon Inc.
- Modality
- Orthosteric Ligands
- Drugs
- anecortave
- Conditions
- exudative age-related macular degeneration
01
Overview
Phase 3, randomised, double-blind trial of anecortave in exudative age-related macular degeneration (4 arms), sponsored by Alcon Inc. Primary endpoint: Best-Corrected Visual Acuity at 12 months. Started Mar 2005; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
15 mg AA q3m
15 mg Anecortave Acetate every 3 months
15 mg AA q6m
15 mg Anecortave Acetate every 6 months
30 mg AA q6m
30 mg Anecortave Acetate every 6 months
Vehicle
Vehicle sham injection every 6 months
03
Who it enrols
Patients 50 years or older with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal choroidal neovascularization (CNV) lesion.
04
Endpoints
Primary
Best-Corrected Visual Acuity
Secondary
Lesion Growth
Beyond the preview
Go deeper on NCT00299507.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299507.